Table 2.
Multivariable Cox Proportional Hazards Regression of the Effect of AIDS Clinical Trials Group 5164 on Antiretroviral Therapy Initiation
| Single predictor |
Multivariable |
|||||
| Factor | HR | 95% CI | P value | HR | 95% CI | P value |
| Age (per 10 years) | 0.99 | 0.82–1.20 | .95 | |||
| Male sex | 1.06 | 0.59–1.72 | .98 | |||
| Race | ||||||
| White | ref | ref | ||||
| Asian | 1.24 | 0.72–2.14 | .44 | 1.32 | 0.75–2.34 | .33 |
| Black | 0.67 | 0.43–1.02 | .06 | 0.69 | 0.42–1.15 | .15 |
| Other | 1.42 | 0.89–2.30 | .14 | 1.00 | 2.77–8.67 | .71 |
| Hispanic ethnicity | 1.28 | 0.88–1.88 | .20 | |||
| CD4 level at PCP diagnosis (per 50 cells/μL) | 0.93 | 0.85–1.02 | .15 | |||
| HIV risk factor | ||||||
| MSM | ref | ref | ||||
| Heterosexual | 0.93 | 0.63–1.38 | .72 | 0.86 | 0.56–1.33 | .50 |
| IDU | 0.60 | 0.35–1.00 | .05 | 0.65 | 0.39–1.08 | .09 |
| Other | 0.40 | 0.20–0.80 | .01 | 0.62 | 0.32–1.21 | .16 |
| Interval | ||||||
| Before ACTG 5164 | ref | ref | ||||
| Between ACTG 5164 and the SFGH 5164 Initiative | 2.81 | 1.77–4.46 | <.01 | 3.05 | 1.86–5.02 | <.01 |
| After the SFGH 5164 Initiative (as compared with before ACTG 5164) | 4.27 | 2.53–7.22 | <.01 | 4.89 | 2.76–8.67 | <.01 |
| After the SFGH 5164 Initiative (as compared with between ACTG 5164 and the SFGH 5164 Initiative) | 1.52 | 0.81–2.86 | .20 | 1.60 | 0.82–3.11 | .16 |
Abbreviations: ACTG, AIDS Clinical Trials Group; CI, confidence interval; HIV, human immunodeficiency virus; HR, hazard ratio; IDU, injection drug user; MSM, men who have sex with men; OR, odds ratio; SFGH, San Francisco General Hospital.